What's Happening?
Zydus Lifesciences Limited has entered into a strategic partnership with Bioeq AG for the U.S. commercialization of NUFYMCO, an interchangeable biosimilar to Lucentis. The U.S. Food and Drug Administration
(USFDA) approved the Biologics License Application for NUFYMCO on December 18, 2025. Under the agreement, Bioeq will handle development, manufacturing, registration, and supply, while Zydus will manage commercialization in the U.S. This partnership aims to expand Zydus' biosimilar business in the U.S., following a recent collaboration with Formycon AG for a Keytruda biosimilar.
Why It's Important?
The partnership between Zydus and Bioeq is significant as it enhances access to affordable ophthalmology care in the U.S. market, which is valued at approximately $210 million. The introduction of NUFYMCO as a biosimilar to Lucentis could provide a cost-effective alternative for patients requiring treatment for conditions like macular degeneration. This move aligns with the broader industry trend of increasing biosimilar availability to reduce healthcare costs and improve patient access to essential medications.
What's Next?
Zydus will focus on leveraging its distribution network and marketing capabilities to ensure the successful launch of NUFYMCO in the U.S. market. The company will likely engage with healthcare providers and insurers to facilitate the adoption of this biosimilar. Additionally, the partnership may prompt further collaborations between Zydus and other biopharmaceutical companies to expand their biosimilar portfolio.
